Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry J Fry

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
Leukemia|December 16, 2024
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemiaTommaso Balestra, Lisa M Niswander, Asen Bagashev, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2006
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cellsSteven A Rosenberg, Claude Sportès, Mojgan Ahmadzadeh, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapyBrynn B Duncan, Steven L Highfill, Haiying Qin, et al.
Blood|May 27, 2016
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignanciesMarianna Sabatino, Jinhui Hu, Michele Sommariva, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 26, 2025
Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CARKole R DeGolier, Catherine Pham-Danis, Samuel D Burciaga, et al.
Blood Advances|August 8, 2022
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomesAiman J Faruqi, John A Ligon, Paul Borgman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignanciesRachel B Salit, Daniel H Fowler, Wyndham H Wilson, et al.
Blood Advances|January 4, 2018
Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathwaysSheryl M Gough, Liat Goldberg, Marbin Pineda, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2019
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell CharacteristicsSandhya R Panch, Sandeep K Srivastava, Nasha Elavia, et al.
Haematologica|February 9, 2018
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphomaHaneen Shalabi, Ira L Kraft, Hao-Wei Wang, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Leukemia|December 16, 2024
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemiaTommaso Balestra, Lisa M Niswander, Asen Bagashev, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2006
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cellsSteven A Rosenberg, Claude Sportès, Mojgan Ahmadzadeh, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapyBrynn B Duncan, Steven L Highfill, Haiying Qin, et al.
Blood|May 27, 2016
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignanciesMarianna Sabatino, Jinhui Hu, Michele Sommariva, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 26, 2025
Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CARKole R DeGolier, Catherine Pham-Danis, Samuel D Burciaga, et al.
Blood Advances|August 8, 2022
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomesAiman J Faruqi, John A Ligon, Paul Borgman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignanciesRachel B Salit, Daniel H Fowler, Wyndham H Wilson, et al.
Blood Advances|January 4, 2018
Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathwaysSheryl M Gough, Liat Goldberg, Marbin Pineda, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2019
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell CharacteristicsSandhya R Panch, Sandeep K Srivastava, Nasha Elavia, et al.
Haematologica|February 9, 2018
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphomaHaneen Shalabi, Ira L Kraft, Hao-Wei Wang, et al.
Pageof 13